There are gene therapy clinical trials occurring with Parkinson's disease patients. In gene therapy, new DNA is delivered to cells using a virus. In the case of the arthritis therapy trial mentioned above it was an adeno-associated virus derived vector that delivered the gene therapy. The Parkinson's GAD clinical trial and the CERE-120 clinical trials both involve a similar adeno-associated virus derived vector.
So, in our quest to help you live better with Parkinson’s disease, we want to give you the facts. Despite our enthusiasm for research, we steadfastly pass along news that may make some readers think twice about participating in a trial. We want readers to think twice about many issues that arise with their health. We want you to ask questions and soak in as much helpful information as possible.
